Effects of an Extended Version of the Lee Silverman Voice Treatment on Voice and Speech in Parkinson’s Disease PurposeThe present study examined vocal SPL, voice handicap, and speech characteristics in Parkinson’s disease (PD) following an extended version of the Lee Silverman Voice Treatment (LSVT), to help determine whether current treatment dosages can be altered without compromising clinical outcomes.MethodTwelve participants with idiopathic PD received the extended treatment version (LSVT-X), ... Clinical Focus
Clinical Focus  |   May 2007
Effects of an Extended Version of the Lee Silverman Voice Treatment on Voice and Speech in Parkinson’s Disease
 
Author Affiliations & Notes
  • Jennifer Spielman
    National Center for Voice and Speech, Denver, CO
  • Lorraine O. Ramig
    University of Coloado at Boulder and National Center for Voice and Speech
  • Leslie Mahler
    University of Coloado at Boulder and National Center for Voice and Speech
  • Angela Halpern
    National Center for Voice and Speech
  • William J. Gavin
    Colorado State University, Fort Collins
  • Contact author: Jennifer Spielman, National Center for Voice and Speech, 1101 13th Street, Denver, CO 80204. E-mail: jspielman@dcpa.org.
  • Leslie Mahler is now at the University of Rhode Island.
    Leslie Mahler is now at the University of Rhode Island.×
  • © 2007 American Speech-Language-Hearing Association
Article Information
Speech, Voice & Prosodic Disorders / Voice Disorders / Special Populations / Older Adults & Aging / Speech, Voice & Prosody / Clinical Focus
Clinical Focus   |   May 2007
Effects of an Extended Version of the Lee Silverman Voice Treatment on Voice and Speech in Parkinson’s Disease
American Journal of Speech-Language Pathology, May 2007, Vol. 16, 95-107. doi:10.1044/1058-0360(2007/014)
History: Received July 7, 2005 , Revised May 9, 2006 , Accepted December 10, 2006
 
American Journal of Speech-Language Pathology, May 2007, Vol. 16, 95-107. doi:10.1044/1058-0360(2007/014)
History: Received July 7, 2005; Revised May 9, 2006; Accepted December 10, 2006
Web of Science® Times Cited: 32
Acknowledgments
This research was supported by Grant R01 DC00150 from the National Institutes of Health. We are extremely grateful to Jill Petska for her help with numerous aspects of this study, and to Elizabeth Coger, Heather Gustafson, Samantha Magnuson, and Marissa McRay for their help with the perceptual study. Finally, special thanks to the participants and families who participated in this study.

PurposeThe present study examined vocal SPL, voice handicap, and speech characteristics in Parkinson’s disease (PD) following an extended version of the Lee Silverman Voice Treatment (LSVT), to help determine whether current treatment dosages can be altered without compromising clinical outcomes.

MethodTwelve participants with idiopathic PD received the extended treatment version (LSVT-X), similar to LSVT except that it was administered twice a week in 1-hr sessions over 8 weeks and required substantially more home practice. Recordings were made in a sound-treated booth immediately before and after treatment, and again 6 months later. Vocal SPL was measured for 4 different tasks and compared with data from a previous study, in which participants with PD received traditional LSVT 4 times a week for 4 weeks. Listener ratings were conducted with audio samples from both studies, using sentence pairs from a standard passage. LSVT-X participants completed the Voice Handicap Index (VHI) before each set of recordings.

ResultsParticipants receiving LSVT-X significantly increased vocal SPL by 8 dB after treatment and maintained increased vocal SPL by 7.2 dB at 6 months. VHI scores improved for 25% of the LSVT-X participants following treatment, and listener ratings indicated audible improvement in speech.

ConclusionsLSVT-X successfully increased vocal SPL (which was consistent with improvements following traditional LSVT), decreased perceived voice handicap, and improved functional speech in individuals with PD. Further large-scale research is required to truly establish LSVT-X efficacy.

Order a Subscription
Pay Per View
Entire American Journal of Speech-Language Pathology content & archive
24-hour access
This Article
24-hour access